gptkbp:instanceOf
|
gptkb:drug
monoamine oxidase inhibitor
|
gptkbp:approvedBy
|
1980s
|
gptkbp:ATCCode
|
gptkb:N04BD02
|
gptkbp:brand
|
gptkb:Eldepryl
gptkb:Emsam
gptkb:Zelapar
|
gptkbp:CASNumber
|
gptkb:14611-51-9
|
gptkbp:chemicalFormula
|
C13H17N
|
gptkbp:contraindication
|
concomitant use with SSRIs
concomitant use with meperidine
concomitant use with tricyclic antidepressants
|
gptkbp:developedBy
|
gptkb:Hungary
|
gptkbp:discoveredBy
|
gptkb:Zoltán_Ecseri
|
gptkbp:discoveredIn
|
1960s
|
gptkbp:eliminationHalfLife
|
10 hours
|
gptkbp:has_stereochemistry
|
(R)-enantiomer
|
https://www.w3.org/2000/01/rdf-schema#label
|
selegiline
|
gptkbp:KEGGID
|
D00268
|
gptkbp:legalStatus
|
prescription only
|
gptkbp:mechanismOfAction
|
irreversible MAO-B inhibitor
|
gptkbp:MeSH_ID
|
gptkb:D015464
|
gptkbp:metabolism
|
gptkb:L-amphetamine
gptkb:L-methamphetamine
liver
|
gptkbp:molecularWeight
|
191.28 g/mol
|
gptkbp:pregnancyCategory
|
C (US)
|
gptkbp:PubChem_CID
|
gptkb:DB01037
gptkb:CHEMBL1062
26757
|
gptkbp:relatedTo
|
gptkb:deprenyl
gptkb:rasagiline
|
gptkbp:routeOfAdministration
|
oral
transdermal
|
gptkbp:sideEffect
|
nausea
dizziness
insomnia
hallucinations
|
gptkbp:UNII
|
6Z5B6HVF6O
|
gptkbp:usedFor
|
gptkb:Alzheimer's_disease
gptkb:Parkinson's_disease
gptkb:major_depressive_disorder
|
gptkbp:bfsParent
|
gptkb:monoamine_oxidase_inhibitors
gptkb:MAO_inhibitors
gptkb:CYP2B6
gptkb:amphetamine
|
gptkbp:bfsLayer
|
6
|